AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Iams Wealth Management LLC

Iams Wealth Management LLC lifted its position in AstraZeneca PLC (NASDAQ:AZN) by 72.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,080 shares of the company’s stock after purchasing an additional 11,369 shares during the period. Iams Wealth Management LLC’s holdings in AstraZeneca were worth $1,774,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. FMR LLC raised its position in AstraZeneca by 1.1% during the third quarter. FMR LLC now owns 23,117,447 shares of the company’s stock worth $1,801,080,000 after acquiring an additional 258,477 shares during the period. Franklin Resources Inc. raised its position in AstraZeneca by 8.7% during the third quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock worth $1,492,649,000 after acquiring an additional 1,522,715 shares during the period. Fisher Asset Management LLC grew its holdings in shares of AstraZeneca by 5.3% during the third quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock worth $816,509,000 after buying an additional 524,175 shares in the last quarter. Clearbridge Investments LLC grew its holdings in shares of AstraZeneca by 5.8% during the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after buying an additional 186,010 shares in the last quarter. Finally, Bank of Montreal Can grew its holdings in shares of AstraZeneca by 109.6% during the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock worth $238,397,000 after buying an additional 1,605,758 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Stock Up 0.7 %

AZN stock opened at $70.06 on Wednesday. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company’s 50 day moving average is $66.69 and its two-hundred day moving average is $74.02. The stock has a market cap of $217.27 billion, a P/E ratio of 33.58, a PEG ratio of 1.13 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter last year, the company earned $0.87 earnings per share. Research analysts expect that AstraZeneca PLC will post 4.12 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.